Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 19, 2023

Treatment-Related Adverse Events in Patients With Solid Tumours Receiving Neoadjuvant and Adjuvant Immune Checkpoint Blockade

The Lancet Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Treatment-related adverse events, including fatal toxicities, in patients with solid tumours receiving neoadjuvant and adjuvant immune checkpoint blockade: a systematic review and meta-analysis of randomised controlled trials
Lancet Oncol 2023 Nov 24;[EPub Ahead of Print], Y Fujiwara, N Horita, E Adib, S Zhou, AH Nassar, ZUA Asad, A Cortellini, AR Naqash

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading